Clinical Trial Update: Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating nodes-sparing short-course radiation combined with CAPOX chemotherapy and tislelizumab for microsatellite-stable middle and low re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Low Rectal Cancer | Phase 2 | Status: RECRUITING